VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.6 EUR | +1.63% |
|
+3.64% | -2.73% |
| 03-20 | Vetoquinol SA Proposes Dividend | CI |
| 03-20 | Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 529M 566M 774M | Sales 2024 * | 553M 591M 808M | Capitalization | 1.18B 1.26B 1.72B |
|---|---|---|---|---|---|
| Net income 2023 | 55M 58.81M 80.39M | Net income 2024 * | 56M 59.88M 81.86M | EV / Sales 2023 | 2.04 x |
| Net cash position 2023 | 130M 139M 190M | Net cash position 2024 * | 184M 196M 268M | EV / Sales 2024 * | 1.8 x |
| P/E ratio 2023 * |
21.4
x | P/E ratio 2024 * |
20.7
x | Employees | 2,497 |
| Yield 2023 |
0.83% | Yield 2024 * |
0.82% | Free-Float | 32.58% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.63% | ||
| 1 week | +3.64% | ||
| Current month | +0.10% | ||
| 1 month | +0.40% | ||
| 3 months | -2.35% | ||
| 6 months | +23.73% | ||
| Current year | -2.73% |
1 week
95.90
100.20
1 month
93.20100.60
Current year
93.20110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 99.6 | +1.63% | 1,805 |
| 24-04-25 | 98 | -1.90% | 4,536 |
| 24-04-24 | 99.9 | +1.01% | 3,388 |
| 24-04-23 | 98.9 | +1.23% | 4,256 |
| 24-04-22 | 97.7 | +1.66% | 2,193 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
99.6
EUR
Average target price
108.4
EUR
Spread / Average Target
+8.85%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.73% | 1.26B | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -2.92% | 3.12B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -14.67% | 1.12B | |
| -5.37% | 990M | |
| -24.06% | 805M |
- Stock Market
- Equities
- VETO Stock
